Auxilium Pharma (NASDAQ: AUXL) was upgraded by MKM Partners from a “neutral” rating to a “buy” rating in a research note issued on Tuesday. The firm currently has a $21.00 price target on the stock, up from their previous price target of $20.00.
A number of other firms have also recently commented on AUXL. Analysts at Canaccord Genuity reiterated a “buy” rating on shares of Auxilium Pharma in a research note to investors on Tuesday. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Auxilium Pharma in a research note to investors on Tuesday, May 15th. They now have a $20.00 price target on the stock. Finally, analysts at Oppenheimer (NYSE: OPY) reiterated a “market perform” rating on shares of Auxilium Pharma in a research note to investors on Friday, May 11st.
Shares of Auxilium Pharma traded down 1.21% during mid-day trading on Tuesday, hitting $18.75. Auxilium Pharma has a 52 week low of $13.59 and a 52 week high of $24.88. The company’s market cap is $905.7 million.
Auxilium Pharma last announced its earnings results on Thursday, May 10th. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.11) by $0.07. Auxilium Pharma’s revenue was up 26.0% compared to the same quarter last year. On average, analysts predict that Auxilium Pharma will post $-0.06 earnings per share next quarter.
Auxilium Pharmaceuticals, Inc. ( Auxilium) is a specialty biopharmaceutical company with a focus on developing and marketing products to predominantly specialist audiences, such as urologists, endocrinologists, certain targeted primary care physicians, hand surgeons, subsets of orthopedic, general, and plastic surgeons who focus on the hand, and rheumatologists.